BFRI - Biofrontera

-

$undefined

N/A

(N/A)

Biofrontera NasdaqCM:BFRI Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Location: 120 Presidential Way, Woburn, MA, 01801, United States | Website: https://www.biofrontera-us.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.237M

Cash

5.912M

Avg Qtr Burn

-2.568M

Short % of Float

0.83%

Insider Ownership

16.92%

Institutional Own.

24.33%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Ameluz (aminolevulinic acid hydrochloride) Details
BCC (basal cell carcinoma), AK (actinic keratosis)

Approved

Quarterly sales

Ameluz®-PDT combo w/ BF-RhodoLED® Details
Superficial basal cell carcinoma

Phase 3

Update

Ameluz® Details
Actinic keratosis

Phase 3

Update

Phase 2

Data readout